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Deﬁbrillation Safety Margin
The Strengths and Limitations of the NCDR ICD Registry*Bruce D. Lindsay, MDF rom the time of the initial clinical reportin 1980 (1), implantable cardioverter-deﬁbril-lators (ICDs) have undergone testing to
conﬁrm that the devices can detect and terminate
ventricular ﬁbrillation (VF). The initial devices were
implanted in the operating room and tested before
discharge in the electrophysiology laboratory. As the
technology evolved, deﬁbrillation threshold testing
was performed in the operating room or the electro-
physiology laboratory at the time of implantation.
The concern was that an ICD might interact with a
coexisting pacemaker, that the ICD might not sense
ventricular tachycardia that fell below the rate detec-
tion criterion, that it might not detect low-amplitude
signals during VF, or that the energy required for
deﬁbrillation might exceed the maximal output of
the ICD (2). With the development of improved lead
technology, biphasic shocks, programmable wave-
forms, higher delivered energy, programmable sensi-
tivity, and integration of pacemakers into ICDs, the
probability of failure has been reduced.
In recent years, the need to perform deﬁbrillation
threshold testing has been questioned because failure
rates are low, the results of testing may not predict
clinical outcomes accurately, and there is some
additional risk (3–5). Moreover, the concept of testing
the deﬁbrillation threshold is only an estimate of
success, because the deﬁbrillation threshold is a* Editorials published in the Journal of the American College of Cardiology
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energy. A common practice is to test 1 or more shocks
at an energy at least 10 J lower than the maximal
output of the ICD system. Advocates of testing
termination of VF by an ICD argue that even if the
failure rate is low, the reported incidence of failure to
convert with a <10-J safety margin is in the range of
4% to 11% (3,4,6). One may argue that physicians who
implant ICDs have an obligation to determine
whether the selected lead conﬁguration can termi-
nate VF, because there are techniques to improve
thresholds. An extensive study in Canada demon-
strated that the risk for serious complications or
mortality associated with testing conversion of VF is
limited to 0.042% (7). Those who advocate deﬁbril-
lation threshold or deﬁbrillation safety margin (DSM)
believe that the beneﬁts outweigh the risk.
If we knew which patients were most likely to have
low energy requirements for deﬁbrillation testing and
which were at risk for failed conversion, we could
focus testing on those at greatest risk. Hsu et al. (8)
analyzed the National Cardiovascular Data Registry
ICD Registry to identify factors predictive of an
inadequate DSM, which was deﬁned as lowest energy
tested <10 J from the maximal device output, and
they evaluated the association of an inadequate DSM
with adverse events. Among the 12,397 patients in
whom DSMs were tested, they were inadequate in
9.4%. Of the 337,547 patients considered for analysis,
the investigators excluded patients who underwent
generator replacement without new leads, those in
whom deﬁbrillator threshold testing was not per-
formed (17.7%), and a small number in whom the
results were not known. The analysis was focused on
the remaining 132,477 patients (39% of the registry
patients considered for analysis) from 1,457 facilities
in whom new leads were inserted and testing was
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266performed. Within this group, they found that
inadequate DSMs were observed in 9.4%. Although
the percent of patients with inadequate DSMs is
higher than in some reports, it is within the range of
values from other published studies.
There are several factors that cannot be deter-
mined from the ICD Registry. The rationale for
testing some patients but not others is not available,
and the impact of drugs on deﬁbrillation thresholds
cannot be assessed, because it is not a required
database element. There could be a bias in the
selection of patients for deﬁbrillation testing, yet
we are left with useful data on a large number of
patients. Moreover, even within the limitations of the
registry data, it is evident that an inadequate DSM
remains problematic.SEE PAGE 256In this issue of the Journal, Hsu et al. (8) found that
the attributes associated with an inadequate DSM are
complex and include age, sex, race, New York Heart
Association functional class, absence of ischemic
heart disease, current renal dialysis, indication for
secondary prevention, and even whether the ICD was
a single-chamber device or a cardiac resynchroniza-
tion therapy deﬁbrillator (8). Using a scoring based on
16 variables, they found that the risk for an inade-
quate DSM increased from 4.9% in the patients at
lowest risk to 24.5% in those with high risk scores.
The ICD Registry does not include structural data
derived from echocardiography or any estimates of
left ventricular mass. Although a scoring system such
as this is imperfect, it would allow some risk esti-
mation that could guide physicians on the need for
testing, appropriate precautions, and the possibilitythat a subcutaneous coil might be required. The in-
vestigators also determined that higher risk scores
were associated with slight increases in procedural
complications, length of stay, and in-hospital mor-
tality. On the basis of these ﬁndings, some low-
volume centers might chose to refer patients with
higher risk scores to more experienced centers for
implantation procedures.
In response to the Centers for Medicare and
Medicaid Services mandate for an ICD registry, the
American College of Cardiology and the Heart Rhythm
Society accepted the responsibility to track implanta-
tion data by developing the National Cardiovascular
Data Registry ICD Registry. The expectation was that
clinical insights could be gained from analysis of a
large number of patients and that it might serve to
measure quality outcomes. The sheer volume of data
acquired by the ICD Registry dwarfs the numbers
generated by single-center or even multicenter
studies. The limitations are that the database ele-
ments do not meet the needs for all inquiries, and only
about 10% of the data are audited for accuracy.
Nonetheless, audits have determined that the quality
of the data is quite good, and within the limits of any
registry, it lends itself to useful clinical studies.
The observations reported by Hsu et al. (8)
undoubtedly will provoke some debate, but it is
a legitimate line of inquiry that serves as an example
of how the ICD Registry can be used to develop
strategies that improve patient outcomes.
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